Drug Trial Radar · NCT01170286
Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy
Last checked: Nov 19, 2026Latest source record: Mar 23, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Jul 2010
Primary completion
Feb 2012
Study completion Feb 2012
Sponsor
- Lead sponsor
- DBV TechnologiesIndustry
- Sponsor type
- Industry
- First posted
- Jul 27, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this phase 1b study is to evaluate the safety and tolerability of repeated epicutaneous applications of peanut proteins using a patch delivery system (Viaskin device) in peanut allergic subjects.
Conditions
- Peanut Allergy
Interventions
Whole peanut extractBiological
Four different doses of whole peanut extract expressed as micrograms (mcg) of peanut proteins (20, 100, 250, 500 mcg) and two different dosing regimen (epicutaneous application for 24 hours every 24 hours and epicutaneous application for 48 hours every 48 hours) will be tested for determination of the maximum tolerated dose during a 2-week treatment period.
Placebo formulationBiological
Matching placebo at two different dosing regimen (epicutaneous application for 24 hours every 24 hours and epicutaneous application for 48 hours every 48 hours) will be tested in parallel to the peanut proteins doses for determination of the maximum tolerated dose during a 2-week treatment period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety evaluationTime frame: Safety evaluation to be performed at each visit during the 2-week treatment and at the follow-up visit one week after the end of treatment.
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Arkansas Children's Hospital
Little Rock, Arkansas
National Jewish Health
Denver, Colorado
CRI Worldwide
Willingboro, New Jersey
Duke University Medical Center
Durham, North Carolina
Aspen Clinical Research
Orem, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.